2 min read
Add as a preferred source on Google

Jaguar Health Posts $2.34 Million in Q3 Revenue and $9.23 Loss Per Share

Product revenue fell to $551,000 while license revenue rose to $1.792 million. Jaguar said its cash could not fund its operating plan for one year after the financial statements were issued.

An unmarked medicine vial and tablet pack sit on a clinic shelf / TokenPost.ai
An unmarked medicine vial and tablet pack sit on a clinic shelf / TokenPost.ai

Jaguar Health, Inc. posted $2.343 million in third-quarter revenue and a $9.23 loss per share, while warning that available cash and management’s plans do not resolve doubt about its ability to continue operating.

For the quarter ended Sept. 30, 2026, revenue declined from $3.083 million in the same period a year earlier. Product revenue fell to $551,000 from $3.041 million, while license revenue climbed to $1.792 million from $42,000. The shift toward license income did not prevent total revenue from falling.

Conditions on a Woodward holdback were met during the quarter, allowing Jaguar to recognize $1.8 million in license revenue and collect the same amount in cash. Woodward accounted for about 98% of Jaguar’s quarterly revenue. Jaguar operates in human and animal health, and its agreements give Woodward exclusive U.S. commercialization rights for Mytesi and Canalevia-CA1.

Jaguar’s consolidated quarterly net loss fell to $5.830 million, compared with $9.648 million a year earlier. Net loss attributable to common stockholders was $6.314 million, and basic and diluted net loss per share was $9.23.

The per-share calculation used a weighted average of 684,374 common shares. A year earlier, the calculation used 4,674 shares and the per-share loss was $2,032.95. Jaguar’s financial statements retroactively adjusted share and per-share amounts for reverse stock splits, so the figures for both periods reflect those adjustments.

Cash stood at $5.528 million on Sept. 30. Jaguar said that balance was insufficient to fund its operating plan for one year after the financial statements were issued. Management concluded its plans “do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”

TokenPost included JAGX in its Nov. 14 premarket earnings schedule.

Jaguar scheduled an investor webcast for Tuesday, Nov. 17, at 8:30 a.m. ET (13:30 UTC) to review its third-quarter results and provide corporate updates.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…